US Regulatory Shift: Wearables Push Supplement Brands into CPSC Jurisdiction, FDA AI Intensifies Scrutiny
Supplement brands entering the US wearables and smart packaging market now face dual regulatory oversight from both the FDA and CPSC, alongside an accelerating FDA use of AI to enhance compliance monitoring and enforcement.
AI-assisted coverage: produced by SF News' automated newsroom from the cited sources and checked by automated attribution gates. Editorial responsibility: Lee Smith, Group CEO. How we work →
Supplement manufacturers expanding into technology-enabled wellness products, such as wearables and smart packaging, in the United States are encountering a significant shift in regulatory oversight. While the FDA retains jurisdiction over products making disease claims or affecting body structure/function, many wellness technologies fall under the US Consumer Product Safety Commission (CPSC).
This dual-agency dynamic introduces new and stringent compliance requirements. CPSC-regulated products necessitate adherence to specific mandatory safety standards, comprehensive product testing, and explicit labelling. Critically, companies must establish robust protocols for 'immediately' reporting product defects that could pose substantial injury risks. Failure to comply can result in severe financial penalties; Fitbit, for example, paid over $12 million for alleged reporting failures concerning smartwatches. Manufacturers must factor in the additional costs of safety assessments and certification, particularly for products containing button-cell batteries or those intended for children, which have stricter lead and phthalate content restrictions.
Concurrently, the FDA is intensifying its regulatory capabilities through the rapid adoption of artificial intelligence. Tools like Elsa, launched in June 2025, and HALO are centralising data across 40+ application and submission sources. Elsa expedites clinical protocol reviews, identifies high-priority inspection targets, and summarises adverse event reports. The FDA's Adverse Event Monitoring System (AEMS) is leveraging AI for cross-product surveillance and consolidating consumer complaints. This technological advancement allows the FDA to process more information faster, pinpointing compliance issues with greater precision across product labels, company websites, and promotional materials.
This increased analytical capacity means that inconsistencies between various company submissions, promotional claims, and post-market data will be more readily identified. Brands must therefore ensure absolute consistency and accuracy across all external communications and internal reporting. The combined regulatory pressure from CPSC's safety mandates and FDA's AI-enhanced scrutiny demands a proactive and integrated approach to product development, compliance, and post-market surveillance.
What this means for United States
US supplement manufacturers diversifying into wearables must integrate CPSC compliance into their product development cycle from inception, allocating budget for mandatory safety testing and certification, potentially increasing R&D costs by 15-20%. Robust post-market surveillance systems are critical to meet CPSC's 'immediate' defect reporting obligations, avoiding multi-million dollar fines. For FDA-regulated products, brand owners must conduct a thorough audit of all marketing claims and label consistency, as FDA's AI tools will accelerate scrutiny of discrepancies. This dual oversight demands heightened diligence in regulatory affairs, requiring expert legal counsel to navigate jurisdictional boundaries and ensure seamless compliance across both agencies. Competitively, early movers with strong compliance frameworks can gain market trust.
This trend is being actively addressed by UK manufacturing partners including Supplement Factory.